Phase 3Status unknown
Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for Injection
A Randomized, Double-blind, Multi-center Phase Ⅲ Comparative Study to Evaluate the Efficacy and Safety of Recombinant Human-mouse Chimeric Anti-TNF-alpha Monoclonal Antibody for Injection.
- Sponsor
- Genor Biopharma Co., Ltd. (Industry)
- Enrolment
- 568 planned
- Conditions
- Rheumatoid Arthritis
- Interventions
- GB242; Infliximab
- Ages
- adults
- Registry
- NCT04178850
Full record on ClinicalTrials.gov
From the registry
This study compares the similarity of the proportion of subjects who achieved ACR20 at week 30 in the two groups.
Primary outcomes
- Number of Participants with ACR20
History
Study completion
Primary completion
Last registry update
Registered
Started